Open-label, randomized, placebo-controlled, Phase 2 study of Nutritional Protocol Including Nicotinamide Riboside Plus Standard of Care in patients with mild-to-moderate COVID-19
Latest Information Update: 13 Oct 2020
Price :
$35 *
At a glance
- Drugs Nicotinamide riboside (Primary) ; Hydroxychloroquine
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors ChromaDex
- 13 Oct 2020 New trial record
- 06 Oct 2020 According to a ChromaDex Media Release, the company look forward to the initiation of a Phase 3 study in the near future.
- 06 Oct 2020 According to a ChromaDex Media Release, The research was conducted in partnership with ScandiBio Therapeutics,This study was led by Dr. Adil Mardinoglu and took place at the Umraniye Teaching and Research Hospital, University of Health Sciences, Istanbul, Turkey. ChromaDex provided NR (patented nicotinamide riboside) for the study, conducted through the ChromaDex External Research Program (CERP).